title: Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol.
abstract: The aim of this study is to investigate the outpatient treatment protocol and radiation safety of a new-emerging lutetium-177 ((177)Lu) prostate specific membrane antigen (PSMA) therapy. This work analyzed the dose rate of 23 patients treated with 7400 MBq (177)Lu-PSMA at different distances (0, 0.25, 0.50, 1.0 and 2.0 m) and variable time marks (0, 1, 2, 4, 18, 24, 48 and 120 h) after the termination of infusion. Blood samples were withdrawn from 17 patients within the same group at 3, 10, 20, 40, 60 and 90 min and 2, 3, 24 h after termination of infusion. Seven different patients were asked to collect urine for 24 h and a gamma well counter was used for counting samples. Family members were invited to wear an optically stimulated luminescence dosimeter whenever they were in the proximity of the patients up to 4-5 d. The total dose of the medical team including the radiopharmacist, physicist, physician, nurse, and nuclear medicine technologist was estimated by an electronic personnel dosimeter. The finger dose was determined using a ring thermoluminescent dosimeter for the radiopharmacist and nurse. The mean dose rate at 1 m after 4 h and 6 h was 23  ±  6 μSv h(-1) and 15  ±  4 μSv h(-1) respectively. The mean total dose to 23 caregivers was 202.3  ±  42.7 μSv (range: 120-265 μSv). The radiation dose of the nurse and radiopharmacist was 6 and 4 μSv per patient, respectively, whereas the dose of the physicist and physician was 2 μSv. The effective half life of blood distribution and early elimination was 0.4  ±  0.1 h and 5  ±  1 h, respectively. Seven patients excreted a mean of 45% (range: 32%-65%) from the initial activity in 6 h. Our findings demonstrate that (177)Lu-PSMA is a safe treatment modality to be applied as an outpatient protocol, since the dose rate decreases below the determined threshold of  <30 μSv h(-1) after approximately 5 h and degrades to 20 μSv h(-1) after 6 h.
authors.affiliation: Department of Nuclear Medicine, Cerrahpasa Medical Faculty, Istanbul University, Cerrahpasa, Fatih, 34098 Istanbul, Turkey.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Demir
authors.forename: Mohammad
authors.initials: M
authors.lastname: Abuqbeitah
authors.forename: Lebriz
authors.initials: L
authors.lastname: Uslu-Beşli
authors.forename: Özlem
authors.initials: Ö
authors.lastname: Yıldırım
authors.forename: Nami
authors.initials: N
authors.lastname: Yeyin
authors.forename: İffet
authors.initials: İ
authors.lastname: Çavdar
authors.forename: Betül
authors.initials: B
authors.lastname: Vatankulu
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Gündüz
authors.forename: Levent
authors.initials: L
authors.lastname: Kabasakal
mesh_terms: D017028:Caregivers; D004151:Dipeptides / Q000627:therapeutic use*; D006573:Heterocyclic Compounds, 1-Ring / Q000627:therapeutic use*; D006801:Humans; D008187:Lutetium; D008297:Male; D016273:Occupational Exposure / Q000032:analysis; D010045:Outpatients; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011829:Radiation Dosage; D011834:Radiation Monitoring / Q000379:methods*; D011879:Radiotherapy Dosage; D017751:Safety Management; D013819:Thermoluminescent Dosimetry; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C000610110:Pluvicto; D004151:Dipeptides; D006573:Heterocyclic Compounds, 1-Ring; D008187:Lutetium; D017430:Prostate-Specific Antigen